missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ PD-L1/4-1BBL Humanized Biosimilar Recombinant Human Monoclonal Antibody

PD-L1/4-1BBL Biosimilar Recombinant Monoclonal Antibody
£483.00 - £2005.00
Specifications
| Antigen | PD-L1/4-1BBL Humanized Biosimilar |
|---|---|
| Concentration | 1 mg/mL |
| Content And Storage | -20°C, Avoid Freeze/Thaw Cycles |
| Applications | ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance |
| Classification | Recombinant Monoclonal |
| Product Code | Brand | Quantity | Price | Quantity & Availability | |||||
|---|---|---|---|---|---|---|---|---|---|
| Product Code | Brand | Quantity | Price | Quantity & Availability | |||||
30282797
![]() |
Invitrogen™
MA560147 |
100 μg |
£483.00
100µg |
Please sign in to purchase this item. Need a web account? Register with us today! | |||||
|
30283110
|
Invitrogen™
MA560148 |
1 mg |
£2005.00
1mg |
Please sign in to purchase this item. Need a web account? Register with us today! | |||||
Description
PD-L1/4-1BBL Biosimilar Recombinant Monoclonal Antibody for SPR, Flow, ELISA, Functional
PD-L1 (Programmed Death-Ligand 1) is a transmembrane protein encoded by the CD274 gene located on chromosome 9p24.1. It is expressed on various cell types, including tumor cells, where it plays a critical role in immune evasion by binding to its receptor PD-1 on T cells, thus inhibiting T cell function and allowing tumor cells to escape immune surveillance. PD-L1 has also been implicated in promoting tumor growth, progression, and radioresistance. On the other hand, 4-1BBL (4-1BB ligand) is a member of the tumor necrosis factor (TNF) superfamily expressed on antigen-presenting cells (APCs) such as dendritic cells, B cells, and macrophages. It is encoded by the TNFSF9 gene on chromosome 19p13.3. 4-1BBL binds to its receptor 4-1BB (CD137) on T cells, providing a co-stimulatory signal that enhances T cell proliferation and survival, as well as cytokine production. The interaction between 4-1BBL and 4-1BB is crucial in the regulation of immune responses, particularly in cancer immunotherapy, where it is leveraged to boost anti-tumor immunity.Specifications
| PD-L1/4-1BBL Humanized Biosimilar | |
| -20°C, Avoid Freeze/Thaw Cycles | |
| Recombinant Monoclonal | |
| Lyophilized | |
| VHH | |
| Human | |
| Primary | |
| Protein A |
| 1 mg/mL | |
| ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance | |
| Unconjugated | |
| Human | |
| RUO | |
| 25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2 | |
| Antibody |
Spot an opportunity for improvement?Share a Content Correction
Product Content Correction
Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title